These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30661214)

  • 1. Targeting the Dopaminergic System in Autoimmunity.
    Vidal PM; Pacheco R
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):57-73. PubMed ID: 30661214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.
    Melnikov M; Rogovskii V; Boykо A; Pashenkov M
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):37-47. PubMed ID: 31011885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.
    Matt SM; Gaskill PJ
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):114-164. PubMed ID: 31077015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine, T cells and multiple sclerosis (MS).
    Levite M; Marino F; Cosentino M
    J Neural Transm (Vienna); 2017 May; 124(5):525-542. PubMed ID: 28283756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases.
    Levite M
    Acta Physiol (Oxf); 2016 Jan; 216(1):42-89. PubMed ID: 25728499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
    Melnikov M; Pashenkov M; Boyko A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunoregulatory role of dopamine: an update.
    Sarkar C; Basu B; Chakroborty D; Dasgupta PS; Basu S
    Brain Behav Immun; 2010 May; 24(4):525-8. PubMed ID: 19896530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine, Immunity, and Disease.
    Channer B; Matt SM; Nickoloff-Bybel EA; Pappa V; Agarwal Y; Wickman J; Gaskill PJ
    Pharmacol Rev; 2023 Jan; 75(1):62-158. PubMed ID: 36757901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic Pathways in Obesity-Associated Inflammation.
    Leite F; Ribeiro L
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):93-113. PubMed ID: 31317376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic Stimulation of Myeloid Antigen-Presenting Cells Attenuates Signal Transducer and Activator of Transcription 3-Activation Favouring the Development of Experimental Autoimmune Encephalomyelitis.
    Prado C; Gaiazzi M; González H; Ugalde V; Figueroa A; Osorio-Barrios FJ; López E; Lladser A; Rasini E; Marino F; Zaffaroni M; Cosentino M; Pacheco R
    Front Immunol; 2018; 9():571. PubMed ID: 29619030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.
    Steiger M
    Eur J Neurol; 2008 Jan; 15(1):6-15. PubMed ID: 18042245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
    Abramsky O; Litvin Y
    Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium channels, memory T cells, and multiple sclerosis.
    Beeton C; Chandy KG
    Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic Regulation of Innate Immunity: a Review.
    Pinoli M; Marino F; Cosentino M
    J Neuroimmune Pharmacol; 2017 Dec; 12(4):602-623. PubMed ID: 28578466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic benefits of regulating inflammation in autoimmunity.
    Nikoopour E; Schwartz JA; Singh B
    Inflamm Allergy Drug Targets; 2008 Sep; 7(3):203-10. PubMed ID: 18782028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Dopamine Receptors in Immune Regulatory Cells.
    Arce-Sillas A; Sevilla-Reyes E; Álvarez-Luquín DD; Guevara-Salinas A; Boll MC; Pérez-Correa CA; Vivas-Almazan AV; Rodríguez-Ortiz U; Castellanos Barba C; Hernandez M; Fragoso G; Sciutto E; Cárdenas G; Adalid-Peralta LV
    Neuroimmunomodulation; 2019; 26(3):159-166. PubMed ID: 31311029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats.
    Popovic M; Stanojevic Z; Tosic J; Isakovic A; Paunovic V; Petricevic S; Martinovic T; Ciric D; Kravic-Stevovic T; Soskic V; Kostic-Rajacic S; Shakib K; Bumbasirevic V; Trajkovic V
    J Neurochem; 2015 Oct; 135(1):125-38. PubMed ID: 26083644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.
    Martin R; Sospedra M; Rosito M; Engelhardt B
    Eur J Immunol; 2016 Sep; 46(9):2078-90. PubMed ID: 27467894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.